CD37 Antibody

What is CD37 and what is its expression pattern across hematologic cell populations?

CD37 is a tetraspanin protein predominantly expressed on the surface of mature B cells. It represents a lineage-specific B-cell antigen that is abundant on B cells but absent in hematopoietic stem cells and plasma cells . This restricted expression pattern makes it an attractive therapeutic target for B-cell malignancies while potentially sparing stem cells from treatment-related toxicity.

To characterize CD37 expression in research settings, flow cytometry using specific antibodies such as HH1 and M-B371 is commonly employed. In comparative studies, the HH1 anti-CD37 antibody has demonstrated superior detection capabilities compared to other antibodies like M-B371, which may show negative-to-weak signals in some cell lines like the pro-monocytic myeloid leukemia cell line U-937 .

For more comprehensive analysis, researchers typically use a panel of approximately 40 markers to identify phenotypic cell subsets, allowing for characterization of CD37 expression in context with other relevant markers in both malignant and healthy cell populations .

How has CD37 expression been characterized in acute myeloid leukemia (AML)?

Contrary to the traditional view of CD37 as a B-cell restricted marker, recent research has demonstrated its expression in AML samples. Studies have investigated CD37 expression in AML using different anti-CD37 antibodies like HH1, revealing its presence in the majority of AML patient samples .

The methodological approach to characterizing CD37 in AML involves:

• Testing surface expression using multiple antibody clones

• Comparing CD37 positivity to validated CAR targets like CD33 and CD123

• Detecting CD37 in leukemic stem cell (LSC) populations

• Examining CD37 expression in relation to European LeukemiaNet (ELN) 2017 risk classification

Research has shown that CD37 protein expression correlates with ELN 2017 patient prognostic stratification, suggesting potential clinical relevance beyond simply serving as a therapeutic target . This correlation differs from other markers like CD33, highlighting CD37's unique association with disease risk stratification.

What mechanisms of action characterize anti-CD37 antibody therapies?

Anti-CD37 antibodies employ multiple mechanisms of action to target malignant cells:

• Apoptosis induction: CD37-targeting therapies can directly induce apoptosis, particularly in the presence of a cross-linker. This occurs through a novel caspase-independent pathway that depends on signal transduction and tyrosine phosphorylation of specific proteins .

• Antibody-dependent cellular cytotoxicity (ADCC): CD37 antibodies mediate ADCC against B-cell malignancies, with efficacy dependent on natural killer (NK) cells rather than naive or activated monocytes. Studies have shown that CD37-SMIP demonstrates ADCC against B-cell leukemia/lymphoma cell lines and primary chronic lymphocytic leukemia (CLL) cells that is superior to therapeutic antibodies like rituximab and alemtuzumab .

• Complement-dependent cytotoxicity (CDC): Some engineered anti-CD37 antibodies are designed to enhance CDC activity.

• Antibody-dependent cell-mediated phagocytosis (ADCP): Although some antibodies demonstrate phagocytic efficacy, this has not been consistently observed with all CD37-targeting approaches .

The effectiveness of these mechanisms appears to be directly proportionate to CD37 surface antigen expression levels, highlighting the importance of characterizing target expression in research and clinical applications .

How do engineered anti-CD37 antibodies compare to standard anti-CD20 therapies?

Comparative studies between anti-CD37 and anti-CD20 (e.g., rituximab, obinutuzumab) antibodies have revealed several important differences:

• Efficacy in resistant populations: Anti-CD37 therapies may offer superior efficacy in CLL, where rituximab mediates relatively poor ADCC .

• Selectivity profile: CD37-targeted approaches demonstrate B-cell selectivity that contrasts with less selective agents like alemtuzumab (anti-CD52), potentially offering an improved safety profile .

• Mechanism of action differentiation: CD37-targeted therapies induce apoptosis through pathways distinct from those utilized by anti-CD20 antibodies. For instance, while tyrosine kinase inhibitors like herbimycin enhance rituximab-mediated apoptosis, they can actually protect against CD37-SMIP–mediated apoptosis .

• Effector function optimization: Next-generation anti-CD37 antibodies incorporate Fc engineering and N-glycan modifications specifically designed to enhance effector functions, potentially surpassing the capabilities of conventional anti-CD20 antibodies .

In xenograft models using human FcRn (Tg32) expressing mice with disseminated Daudi tumors, comparative efficacy studies have been conducted between humanized anti-CD37 antibodies and established therapies like obinutuzumab and DuoHexaBody-CD37 .

What approaches have been developed for engineering enhanced anti-CD37 antibodies?

Several engineering approaches have been developed to optimize anti-CD37 antibodies:

• Small Modular Immunopharmaceuticals (SMIPs): These molecules incorporate variable regions (VL and VH) from antibodies like G28-1 hybridoma linked to modified human IgG1 domains (hinge, CH2, and CH3). This design maintains a molecular weight above the glomerular filtration threshold to prevent rapid elimination while enhancing production efficiency .

• Humanization of antibodies: Conversion of murine antibodies to humanized versions (e.g., NNV029, NNV031, and NNV032) reduces immunogenicity while preserving target binding .

• Fc engineering: Modifications to the Fc region enhance binding to Fcγ receptors, improving effector functions like ADCC and ADCP .

• N-glycan engineering: Optimization of glycosylation patterns improves effector functions and extends plasma half-life .

• Bi-paratopic antibody development: DuoHexaBody-CD37 represents a bi-paratopic approach that may enhance binding and efficacy .

These engineering strategies address key challenges in antibody development, including production efficiency, pharmacokinetics, and therapeutic efficacy, ultimately aiming to create CD37-targeted therapies with improved clinical outcomes compared to existing treatments.

How is CD37 expression being evaluated as a biomarker in hematological malignancies?

Recent research has investigated CD37's potential as a biomarker, particularly in AML:

• Expression correlation with risk stratification: Studies have demonstrated that CD37 protein expression correlates with the European LeukemiaNet (ELN) 2017 patient prognostic stratification in AML, suggesting its utility as a predictive biomarker. This correlation was superior to that observed with CD33, a commonly targeted antigen in AML .

• Association with disease outcomes: Research titled "CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia" suggests that CD37 expression levels may predict treatment response and patient outcomes .

• Methodological approaches: Evaluation of CD37 as a biomarker typically involves:

  • Flow cytometry analysis of primary patient samples

  • Correlation of expression levels with clinical parameters

  • Comparison with established prognostic markers

  • Assessment in defined patient subpopulations (e.g., leukemic stem cells)

• Applications in therapy selection: CD37 expression analysis may guide therapy selection, particularly for CD37-directed treatments, similar to how CD20 expression informs rituximab use in B-cell malignancies.

This emerging area of research suggests that CD37 may serve dual roles as both a therapeutic target and a prognostic biomarker, potentially allowing for more personalized treatment approaches in hematological malignancies .

What are the current challenges in developing CD37-directed CAR-T cell therapies?

The development of CD37-directed CAR-T cell therapies presents several unique challenges that researchers are actively addressing:

• Target expression heterogeneity: While CD37 is expressed in the majority of AML patients, expression levels can vary significantly. This heterogeneity necessitates comprehensive screening of patient samples to identify those most likely to benefit from CD37-directed CAR-T therapy .

• On-target/off-tumor toxicity: Although CD37 expression was traditionally considered B-cell restricted, its detection in AML and T-cell lymphomas raises concerns about potential off-tumor effects. Researchers must carefully evaluate CD37 expression across normal tissues to predict and mitigate toxicity risks .

• CAR design optimization: Optimal CAR design requires selection of CD37 antibody domains with appropriate affinity and specificity. The HH1 anti-CD37 antibody has shown promise as a basis for CAR development due to its superior detection capabilities compared to other antibodies like M-B371 .

• Comparison with established targets: Researchers must demonstrate advantages of CD37-directed CAR-T cells over approaches targeting established antigens like CD33 or CD123 in AML. Current research suggests that CD37's correlation with ELN 2017 risk stratification may offer prognostic benefits not seen with CD33 .

• Resistance mechanisms: Understanding potential resistance mechanisms, including downregulation of CD37 expression or emergence of CD37-negative clones, remains critical for developing effective CAR-T cell therapies with durable responses.

Ongoing preclinical and clinical studies will continue to address these challenges to determine the optimal positioning of CD37-directed CAR-T cell therapies in the treatment landscape for hematological malignancies.

How do Fc engineering and glycoengineering approaches enhance anti-CD37 antibody efficacy?

Advanced antibody engineering techniques have significantly improved the therapeutic potential of anti-CD37 antibodies:

• Fc engineering for enhanced effector functions:

  • Specific modifications to the Fc region alter binding affinity to Fcγ receptors

  • Enhanced ADCC activity is achieved through optimized FcγRIIIa binding

  • Modified Fc domains can improve CDC through enhanced C1q recruitment

  • These modifications can be assessed using in vitro binding assays measuring interaction with various Fcγ receptors

• Glycoengineering for pharmacokinetic optimization:

  • N-glycan modifications influence antibody half-life and tissue distribution

  • Specific glycoform profiles can enhance FcRn binding and recycling

  • Human endothelial recycling assay (HERA) provides a method to evaluate FcRn binding and transport properties

  • In vivo studies in human FcRn (Tg32) expressing mice validate improvements in pharmacokinetic properties

• Combining engineering approaches:

  • Humanized anti-CD37 IgG1 antibodies (NNV029, NNV031, and NNV032) incorporate both Fc engineering and N-glycan modifications

  • These dual modifications produce antibodies with both enhanced effector functions and extended plasma half-life

  • Comparative studies against standard therapies demonstrate advantages of these engineering approaches

These advanced engineering strategies are critical for developing next-generation CD37 antibodies that overcome limitations of earlier therapeutic approaches and potentially offer improved clinical outcomes in hematological malignancies.

What factors influence the efficacy of CD37 antibodies in different disease settings?

The efficacy of CD37-targeted antibody therapies varies across different hematological malignancies due to several critical factors:

• Target expression levels: The effectiveness of CD37 antibody therapies correlates directly with CD37 surface expression levels. Research has demonstrated that apoptosis induction by CD37-SMIP is proportionate to CD37 antigen density, highlighting the importance of expression analysis in predicting response .

• Effector cell populations: Natural killer (NK) cells play a crucial role in mediating CD37 antibody efficacy through ADCC. Studies have shown that NK cell depletion in mouse models results in diminished therapeutic efficacy, underscoring the importance of functional effector cell populations .

• FcγR polymorphisms: While not explicitly studied for CD37 antibodies, research with other therapeutic antibodies indicates that FcγRIIIa polymorphisms associated with enhanced ADCC correlate with superior clinical responses. Investigation of how these polymorphisms affect CD37 antibody efficacy represents an important area for future research .

• Disease biology: The efficacy of CD37 antibodies varies across disease settings. For instance, CD37-SMIP has demonstrated superior ADCC against CLL cells compared to rituximab and alemtuzumab, despite rituximab's established efficacy in other B-cell malignancies .

• Combination approaches: The integration of CD37 antibodies into combination regimens may enhance efficacy. Future studies examining synergistic effects with chemotherapy, small molecule inhibitors, or other antibody therapies will be crucial for optimizing therapeutic outcomes.

Understanding these factors will enable researchers to develop personalized treatment approaches that maximize the potential of CD37-targeted therapies across different hematological malignancies.

How might CD37 antibodies be repurposed for treatment of AML?

The discovery of CD37 expression in AML has opened new possibilities for repurposing CD37-targeted therapies:

• Validation of expression: Comprehensive studies have confirmed CD37 expression in AML patient samples using multiple antibody clones, with expression levels comparable to established AML targets like CD33 and CD123 .

• Expression in leukemic stem cells: CD37 has been detected in AML leukemic stem cell (LSC) populations, suggesting potential efficacy against disease-initiating cells responsible for relapse .

• Correlation with risk stratification: CD37 protein expression shows excellent correlation with ELN 2017 patient prognostic stratification, potentially allowing for targeted therapy in higher-risk patients .

• CAR-T repurposing approach: Anti-lymphoma CD37CAR has been repurposed for AML treatment, demonstrating that CD37CAR T cells specifically kill AML cells, secrete pro-inflammatory cytokines, and control cancer progression in preclinical models .

• Safety profile: The restricted expression pattern of CD37 may offer safety advantages over targets like CD33 or CD123, which are expressed on normal hematopoietic stem cells and may lead to prolonged cytopenias when targeted .

This repurposing strategy exemplifies how detailed characterization of antigen expression across different malignancies can reveal unexpected therapeutic opportunities, potentially expanding the utility of existing CD37-directed approaches beyond their originally intended applications.

What novel antibody formats are being explored for CD37-targeted therapies?

Research is advancing beyond conventional antibodies to explore innovative formats targeting CD37:

• Small Modular Immunopharmaceuticals (SMIPs): These engineered proteins combine variable regions with modified constant regions, offering advantages in production efficiency and pharmacokinetics while maintaining therapeutic efficacy. The CD37-SMIP has demonstrated potent apoptosis induction and superior ADCC against CLL cells compared to rituximab and alemtuzumab .

• Bi-paratopic antibodies: DuoHexaBody-CD37 represents a bi-paratopic approach currently in Phase I clinical development. This format may enhance binding avidity and therapeutic efficacy through simultaneous engagement of multiple epitopes .

• Antibody-drug conjugates (ADCs): Naratuximab emtansine combines anti-CD37 targeting with a cytotoxic payload, allowing for direct delivery of chemotherapy to CD37-expressing cells. Clinical testing has shown efficacy in NHL patients .

• Radioimmunotherapy (RIT): Betalutin, a CD37-targeting radioimmunotherapy, delivers radiation directly to CD37-expressing cells, offering an alternative mechanism for eliminating malignant B-cells. Clinical testing has demonstrated efficacy in NHL patients .

• Glycoengineered antibodies: Humanized anti-CD37 IgG1 antibodies with optimized N-glycan profiles represent another avenue for enhancing therapeutic efficacy through improved effector functions and pharmacokinetics .

These diverse approaches highlight the versatility of CD37 as a therapeutic target and demonstrate the potential for tailoring antibody format to specific disease contexts and desired mechanisms of action.